Acquisition by Foletta Mark G of 10800 shares of Enanta Pharmaceuticals at 47.72 subject to Rule 16b-3

ENTA Stock  USD 8.56  0.45  4.99%   
About 66% of Enanta Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Enanta Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Enanta Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Enanta Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Enanta Pharmaceuticals Director. Grant, award or other acquisition pursuant to Rule 16b-3

Read at macroaxis.com
Acquisition of 10800 stock option (right to buy) at 47.72 of Enanta Pharmaceuticals by Foletta Mark G on 22nd of March 2024. This event was filed by Enanta Pharmaceuticals with SEC on 2023-03-02. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Enanta Pharmaceuticals' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Enanta Pharmaceuticals' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Enanta Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Enanta Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Enanta Pharmaceuticals Fundamental Analysis

We analyze Enanta Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Enanta Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Enanta Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Return On Asset

Return On Asset Comparative Analysis

Enanta Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Enanta Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Enanta Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Enanta Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Enanta Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Enanta Pharmaceuticals Related Equities

DSGNDesign Therapeutics   9.43   
0%
100.0%
INBXInhibrx   3.97   
0%
42.0%
IPSCCentury Therapeutics   3.85   
0%
40.0%
RVMDRevolution Medicines   1.97   
0%
20.0%
CGEMCullinan Oncology   1.83   
0%
19.0%
GLUEMonte Rosa   1.65   
0%
17.0%
CRNXCrinetics Pharmaceuticals   1.21   
0%
12.0%
LYELLyell Immunopharma   1.10   
0%
11.0%
MRUSMerus BV   1.06   
0%
11.0%
EWTXEdgewise Therapeutics   0.31   
0%
3.0%
STOKStoke Therapeutics   0.08   
1.0%
0%
IKNAIkena Oncology   1.16   
12.0%
0%
MLYSMineralys Therapeutics,   1.42   
15.0%
0%
HOWLWerewolf Therapeutics   2.00   
21.0%
0%
KRONKronos Bio   2.25   
23.0%
0%
CCCCC4 Therapeutics   4.34   
46.0%
0%

Complementary Tools for Enanta Stock analysis

When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
CEOs Directory
Screen CEOs from public companies around the world
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance